Skip to main content
Premium Trial:

Request an Annual Quote

Gene Security Raises $12M in Series C Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gene Security Networks today said it has closed on a $12 million Series C round of financing, which it will use to bring its gene testing technology to new markets.

Sequoia Capital led the round, which included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.

The company, based in Redwood City, Calif., uses data informatics to "enhance genetic testing of DNA," Gene Security said in a statement. Using its Parental Support tests to diagnose the genetic state of a single cell from an embryo, the firm has established a leadership position in the in vitro fertilization market, it added.

In a statement, Matthew Rabinowitz, president and CEO of Gene Security, said, "The new investment will accelerate the application of our Parental Support technology beyond the fertility market into areas such as prenatal diagnostics, which crucially needs tests with enhanced accuracy and coverage."

Of the 4 million births annually in the US, more than 1 percent results from in vitro fertilization, the company said, and 3 to 5 percent of all children born in the US have birth defects or some form of genetic illness.

Gene Security is "now in a strong position to expand and deliver revolutionary tools to the broader reproductive industry," said Roelof Botha, a partner in Sequoia Capital.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.